Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice

International Immunopharmacology

Volumn 7, Issue 6, 2007, Pages 773-780

  Jan, Tong Rong ^a   Su, Shu Ting ^a   Wu, Hsin Ying ^a   Liao, Mei Hsiu ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

Antibody production; Cannabidiol; Cytokine; Ovalbumin; Splenocyte

Indexed keywords

ANTIBODY; ANTIGEN; CALCIUM IONOPHORE; CANNABIDIOL; CANNABIS; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 4; OVALBUMIN; PHORBOL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; CELL ACTIVITY; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; EX VIVO STUDY; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SINGLE DRUG DOSE; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; CANNABIDIOL; CELL PROLIFERATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; MALE; MICE; MICE, INBRED BALB C; OVALBUMIN; SPLEEN; T-LYMPHOCYTES;

EID: 34247359068     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.01.015     Document Type: Article

References (43)

1. Cabral G.A., and Staab A. Effects on the immune system. Handb Exp Pharmacol (2005) 385-423
2. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., et al. The cannabinoid system and immune modulation. J Leukoc Biol 74 (2003) 486-496
3. Mechoulam R. Marihuana chemistry. Science 168 (1970) 1159-1166
4. Straus S.E. Immunoactive cannabinoids: therapeutic prospects for marijuana constituents. Proc Natl Acad Sci U S A 97 (2000) 9363-9364
5. Mechoulam R., and Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121 (2002) 35-43
6. Strasser F., Luftner D., Possinger K., Ernst G., Ruhstaller T., Meissner W., et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24 (2006) 3394-3400
7. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., and Guimaraes F.S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39 (2006) 421-429
8. Russo E., and Guy G.W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66 (2006) 234-246
9. Klein T.W., Newton C., Zhu W., Daaka Y., and Friedman H. Delta 9-tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc Soc Exp Biol Med 209 (1995) 205-212
10. Mishkin E.M., and Cabral G.A. Delta-9-tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J Gen Virol 66 Pt 12 (1985) 2539-2549
11. Morahan P.S., Klykken P.C., Smith S.H., Harris L.S., and Munson A.E. Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infect Immun 23 (1979) 670-674
12. Herring A.C., Koh W.S., and Kaminski N.E. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem Pharmacol 55 (1998) 1013-1023
13. Schatz A.R., Koh W.S., and Kaminski N.E. Delta 9-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology 26 (1993) 129-137
14. McCoy K.L., Matveyeva M., Carlisle S.J., and Cabral G.A. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther 289 (1999) 1620-1625
15. Baczynsky W.O., and Zimmerman A.M. Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. II. In vitro investigation using cultured mouse splenocytes. Pharmacology 26 (1983) 12-19
16. Baczynsky W.O., and Zimmerman A.M. Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. I. In vivo investigation of the primary and secondary immune response. Pharmacology 26 (1983) 1-11
17. Zimmerman S., Zimmerman A.M., Cameron I.L., and Laurence H.L. Delta1-tetrahydrocannabinol, cannabidiol and cannabinol effects on the immune response of mice. Pharmacology 15 (1977) 10-23
18. Smith M.S., Yamamoto Y., Newton C., Friedman H., and Klein T. Psychoactive cannabinoids increase mortality and alter acute phase cytokine responses in mice sublethally infected with Legionella pneumophila. Proc Soc Exp Biol Med 214 (1997) 69-75
19. Jan T.R., Rao G.K., and Kaminski N.E. Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. Mol Pharmacol 61 (2002) 446-454
20. Kaplan B.L., Rockwell C.E., and Kaminski N.E. Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J Pharmacol Exp Ther 306 (2003) 1077-1085
21. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 97 (2000) 9561-9566
22. Weiss L., Zeira M., Reich S., Har-Noy M., Mechoulam R., Slavin S., et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39 (2006) 143-151
23. Beck L., and Spiegelberg H.L. The polyclonal and antigen-specific IgE and IgG subclass response of mice injected with ovalbumin in alum or complete Freund's adjuvant. Cell Immunol 123 (1989) 1-8
24. Morokata T., Ishikawa J., and Yamada T. Antigen dose defines T helper 1 and T helper 2 responses in the lungs of C57BL/6 and BALB/c mice independently of splenic responses. Immunol Lett 72 (2000) 119-126
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
26. Ouyang Y.L., Azcona-Olivera J.I., and Pestka J.J. Effects of trichothecene structure on cytokine secretion and gene expression in murine CD4+ T-cells. Toxicology 104 (1995) 187-202
27. Sacerdote P., Martucci C., Vaccani A., Bariselli F., Panerai A.E., Colombo A., et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 159 (2005) 97-105
28. Mosmann T.R., and Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7 (1989) 145-173
29. El-Gohary M., and Eid M.A. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum Exp Toxicol 23 (2004) 149-156
30. Finkelman F.D., Holmes J., Katona I.M., Urban Jr. J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8 (1990) 303-333
31. Seki N., Sudo Y., Yoshioka T., Sugihara S., Fujitsu T., Sakuma S., et al. Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J Immunol 140 (1988) 1477-1484
32. Mauri C., Williams R.O., Walmsley M., and Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 26 (1996) 1511-1518
33. Watzl B., Scuderi P., and Watson R.R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol 13 (1991) 1091-1097
34. Nakano Y., Pross S., and Friedman H. Contrasting effect of delta-9-tetrahydrocannabinol on IL-2 activity in spleen and lymph node cells of mice of different ages. Life Sci 52 (1993) 41-51
35. Srivastava M.D., Srivastava B.I., and Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40 (1998) 179-185
36. Pacifici R., Zuccaro P., Pichini S., Roset P.N., Poudevida S., Farre M., et al. Modulation of the immune system in cannabis users. JAMA 289 (2003) 1929-1931
37. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
38. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
39. Wiley J.L., and Martin B.R. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 121 (2002) 57-63
40. Sumariwalla P.F., Gallily R., Tchilibon S., Fride E., Mechoulam R., and Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 50 (2004) 985-998
41. Bloom A.S., Edgemond W.S., and Moldvan J.C. Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes. Neurochem Res 22 (1997) 563-568
42. Makriyannis A., Yang D.P., Griffin R.G., and Das Gupta S.K. The perturbation of model membranes by (-)-delta 9-tetrahydrocannabinol. Studies using solid-state 2H- and 13C-NMR. Biochim Biophys Acta 1028 (1990) 31-42
43. Carrier E.J., Auchampach J.A., and Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 103 (2006) 7895-7900